Bibliografía
Acladious NN, Sutton C, Mandal D, Hopkins R, Zaklama M, Kitchener H. Persistent human papillomavirus infection and smoking increase risk of failure of treatment of cervical intraepithelial neoplasia (CIN). Int J Cancer 2002;98:435-439.
Aristizabal N, Cuello C, Correa P. The impact of vaginal cytology on cervical cancer risks in Cali, Colombia. Int J Cancer 1984;34:5-9.
ASCUS-LSIL Traige Study (ALTS) Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. J Natl Cancer Inst. 2000;92:397-402.
ASCUS-LSIL Traige Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol. 2003;188:1393-1400.
ASCUS-LSIL Traige Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 2003;188:1383-1392. Bauer HM, Ting Y, Greer CE, et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 1991;265:472–477.
Bray F, Loos AH, McCarron P, Weiderpass E, Arbyn M, Moller H, Hakama M, Parkin DM. Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev. 2005;14:677-686.
Brink AA, Zielinski GD, Steenbergen RD, Snijders PJ, Meijer CJ. Clinical relevance of human papillomavirus testing in cytopathology. Cytopathology 2005 ;16:7-12.
Bosch FX, Castellsague X, Muñoz N, et al. Male sexual behavior and human papillomavirus DNA: key risk factors for cervical cancer in Spain. J Natl Cancer Inst 1996;88:1060-1067.
Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-265.
Bosch FX, Manos MM, Muñoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995;87:796-802.
Bosch FX, Muñoz N, de Sanjose S, et al. Risk factors for cervical cancer in Colombia and Spain. Int J Cancer 1992;52:750-758.
Bosch FX, Muñoz N, de Sanjosé S, et al. Human papillomavirus and cervical intraepithelial neoplasia grade III/carcinoma in situ: a case-control study in Spain and Colombia. Cancer Epidemiol Biomarkers Prev 1993;2:415-422.
Bosch FX, de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer--burden and assessment of causality. J Natl Cancer Inst Monogr. 2003;(31):3-13.
Brown AD, Garber AM. Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing. JAMA 1999;281:347-353.
Bulkmans NW, Rozendaal L, Voorhorst FJ, Snijders PJ, Meijer CJ. Long-term protective effect of high-risk human papillomavirus testing in population-based cervical screening. Br J Cancer. 2005;92:1800-1802.
Carozzi F, Ronco G, Confortini M, Noferini D, Maddau C, Ciatto S, et al. Prediction of high-grade cervical intraepithelial neoplasia in cytologically normal women by human papillomavirus testing. Br J Cancer 2000;83:1462-1467.
Castellsague X, Bosch FX, Munoz N, Meijer CJ, Shah KV, de Sanjose S, et al; The International Agency for Research on Cancer Multicenter Cervical Cancer Study Group.Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med. 2002;346:1105-1112.
Celentano DD, Klassen AC, Weisman CS, et al. Duration of relative protection of screening for cervical cancer. Prev Med 1989;18:411-422.
Cecchini S, Carozzi F, Confortini M, Zappa M, Ciatto S. Persistent human papilloma virus infection as an indicator of risk of recurrence of high-grade cervical intraepithelial neoplasia treated by the loop electrosurgical excision procedure. Tumori. 2004;90:225-228.
Clavel C, Bory JP, Rieht S, Masure M, Duval-Benninger I, Putaud I, et al. Comparative analysis of human papillomavirus detection by hybrid capture assay and routinee cytologic screening to detect high-grade cervical lesions. Int J Cancer 1998;75:525-528.
Clavel C, Masure M, Bory JP, et al. Hybrid capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study of 1581 women. Br J Cancer 1999;80:1306-1311.
Cope JU, Hildesheim A, Schiffman MH, Manos MM, Lorincz AT, Burk RD, et al. Comparison of the hybrid capture tube test and PCR for detection of human papillomavirus DNA in cervical specimens. J Clin Microbiol 1997;35:2262-2265.
Coutlee F, Gravitt P, Kornegay J, Hankins C, Richardson H, Lapointe N, Voyer H, Franco E. Use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples. J Clin Microbiol 2002;40:902-907.
Cramer DW. The role of cervical cytology in the declining morbidity and mortality of cervical cancer. Cancer 1974;34:2018-2027.
Cuzick J. Screening for cancer: future potential. Eur J Cancer 1999;35:1925-1932.
Cuzick J. Time to consider HPV testing in cervical screening. Ann Oncol 2001;12:1511-1514.
Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I, et al. HPV testing in primary screening of older women. Br J Cancer 1999a;81:554-558.
Cuzick J, Sasieni P, Davies P, Adams J, Normand C, Frater A, et al. A systematic review of the role of human papillomavirus testing within a cervical screening programme. Health Technol Assess 1999b;3:1-196.
Cuzick J, Szarewski A, Terry G, et al. Human papillomavirus testing in primary cervical screening. Lancet 1995;345:1533-1536.
Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 2003;362:1871-1876.
Cuzick J, Terry G, Ho L, Hollingworth T, Anderson M. Type-specific human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia. Br J Cancer 1994;69:167-171.
Davey DD, Armenti CA. HPV primary screening for cervical cancer: more pain than protection. Diagn Cytopathol 2000;22:333-335.
De Roda Husman AM, Walboomers JM, Hopman E, et al. HPV prevalence in cytomorphologically normal cervical scrapes of pregnant women as determined by PCR: the age-related pattern. J Med Virol 1995;46:97-102.
Fahey MT, Irwig LM, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol 1995;141:680-689.
Ferlay J, Parkin DM, Pisani P. GLOBOCAN: cancer incidence and mortality worldwide. IARC Cancer Base 3, International Agency for Research on Cancer, Lyon (1998).
Franceschi S, Castellsague X, Dal Maso L, Smith JS, Plummer M, Ngelangel C, et al. Prevalence and determinants of human papillomavirus genital infection in men. Br J Cancer 2002;86:705-711.
Franco EL, Rohan TE, Villa LL. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical carcinoma. J Natl Cancer Inst 1999;91:506-511.
Gaarenstroom KN, Melkert P, Walboomers MM, Brule AJC van den, Bommel PFJ van, et al. Human papillomavirus DNA and genotypes: prognostic factors for progression of cervical intraepithelial neoplasia. Int J Gynecol Oncol 1994;4:73-78.
Gyrd-Hansen D. Estimation of utility associated with participation in cancer screeening programmes”, ponencia presentada a The Second European Conference on the Economics of Cancer, Brussels, September 2000.
Hagmar B, Kalantari M, Skyldberg B, Moberger B, Johansson B, Walaas L, et al. Human papillomavirus in cell samples from Stockholm Gynecologic Health Screening. Acta Cytol 1995;39:741-745.
Hakim Z, Pathak DS. Modelling the Euroqol data: A comparison of discrete conjoint and conditional preference modelling. Health Economics 1999;8:103-116.
Harper DM, Noll WW, Belloni DR, Cole BF. Randomized clinical trial of PCR-determined human papillomavirus detection methods: self-sampling versus clinician-directed--biologic concordance and women's preferences. Am J Obstet Gynecol 2002;186:365-373.
Herbert A. Is cervical screening working? A cytopathologist's view from the United Kingdom. Hum Pathol 1997;28:120-126.
Herbert A. The cervical screening muddle. Lancet 1998;351:1129-1130.
Herrero R, Brinton LA, Reeves WC, et al. Screening for cervical cancer in Latin America: a case-control study. Int J Epidemiol 1992;21:1050-1056.
Hildesheim A, Schiffman MH, Gravitt PE, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;69:235-240.
Hillemanns P, Kimmig R, Huttemann U, Dannecker C, Thaler CJ. Screening for cervical neoplasia by self-assessment for human papillomavirus DNA. Lancet 1999;354:1970.
Hinchliffe SA, van Velzen D, Korporaal H, Kok PL, Boon ME.Transience of cervical HPV infection in sexually active, young women with normal cervicovaginal cytology. Br J Cancer 1995;72:943-945.
Ho GYF, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-1371.
Holowaty P, Miller AB, Rohan T, To T. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999;91:252-258.
Holmes J, Hemmett L, Garfield S. The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies. Eur J Health Econ. 2005;6:30-37.
Howell LP, Belk T, Agdigos R, Davis R, Lowe J. AutoCyte Interactive Screening System. Experience at a university hospital cytology laboratory. Acta Cytol 1999;43:58-64.
http://www.gobcan.es/psc. Gobierno de Canarias. Plan de Salud Canario.
http://www.iarc.fr International Agency for Research on Cancer Working Group on Evaluation of Cervical Cancer Screening Programmes: Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. BMJ 1986;293:659-664.
Jenkins D, Sherlaw-Johnson C, Gallivan S. Can papilloma virus testing be used to improve cervical cancer screening?. Int J Cancer 1996;65:768-773.
Khanna N, Brooks SE, Chen TT, Simsir A, Gordon NJ, Taylor G.Human papillomavirus absence predicts normal cervical histopathologic findings with abnormal Papanicolaou smears: a study of a university-based inner city population. J Hum Virol 2001;4:283-287.
Karlsen F, Kalantari M, Jenkins A, et al. Use of multiples PCR primer sers for optimal detection of human papillomavirus. J Clin Microbiol 1996;34:2095-2100.
Karlsen F, Kalantari M, Jenkins A, Pettersen E, Kristensen G, Holm R, et al. Use of multiple PCR primer sets for optimal detection of human papillomavirus. J Clin Microbiol 1996; 34:2095-2100.
Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 2002;287:2382-2390.
Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. J Natl Cancer Inst. 2005;97:888-895.
Kjaer SK, van den Brule AJ, Bock JE, Poll PA, Engholm G, et al. Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal Pap smear: are there different risk profiles for oncogenic and nononcogenic HPV types?. Cancer Epidemiol Biomarkers Prev 1997;6:799-805.
Kjaer SK, van den Brule AJ, Bock JE, Paull G, Svare EI, Sherman ME, et al. Type specific persistence of high risk human papillomavirus (HPV) as indicators of high grade cervical squamous intraepithelial lesions in young women : population based prospective follow up study. B Med J 2002;325:1-7
Kjellberg L, Hallmans G, Ahren AM, Johansson R, Bergman F, Wadell G, et al. Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br J Cancer 2000;82:1332-1338.
Kleinman JC, Kopstein A: Who is being screened for cervical cancer? Am J Pub Health 1981;71:73-76.
Kleter B, van Doorn LJ, ter Schegget J, et al. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol 1998;153:1731-1739.
Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to Papillomavirus infection. N Engl J Med 1992;327:1272-1278.
Kuhn L, Denny L, Pollack A, Lorincz A, Richart RM, Wright TC. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Natl Cancer Inst 2000;92:818-825.
Kyo S, Inoue M, Koyama M, Fujita M, Tanizawa O, Hakura A. Detection of high-risk human papillomavirus in the cervix and semen of sex partners. J Infect Dis 1994;170:682-685.
Läärä E, Day NE, Hakama M. Trends in mortality from cervical cancer in the Nordic countries: associations with organized screening programmes. Lancet 1987;i:1247-1249.
Lazo P. The molecular genetics of cervical carcinoma. Br J Cancer 1999;80:2008-2018.
Liaw K-L, Glass AG, Manos M, Greer CE, Scott DR, Sherman M, et al. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst 1999;91:954-960.
Lynge E. Regional trends in incidence of cervical cancer in Denmark in relation to local smear-tqaking activity. Int J Epidemiol 1983;12:405-413.
Mandelblatt JS, Lawrence WF, Womack SM, Jacobson D, Yi B, Hwang YT, Gold K, Barter J, Shah K. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002;287:2372-2381.
Mango LJ, Radensky PW. Interactive neural network-assisted screening. Acta Cytol 1998;42:233-245.
McIndoe WA, McLean MR, Jones RW, Mullins PR. The invasive potential of carcinoma in situ of the cervix. Obstet Gynecol 1984;64:451-458.
McIntosh et al. Using discrete choice experiments within a cost-utility analysis framework. Health Economics Study Group Meeting, University of Nottingham, Julio 2000.
Meijer CJ, van den Brule AJ, Snijders PJ, Helmerhorst T, Kenemans P, Walboomers JM. Detection of human papillomavirus in cervical scrapes by the polymerase chain reaction in relation to cytology: possible implications for cervical cancer screening. IARC Sci Publ 1992;119:271-281.
Meijer CJLM, Helmerhorst ThJM, Rozendaal L, van der Linden JC, Voorhorst FJ, Walboomers JMM. HPV typing adn testing in gynecological pathology: has the time come?. Histopathology 1998;33:83-86.
Meijer CJLM, Walboomers JMM. Cervical cytology after 2000: where to go?. J Clin Pathol 2000;53:41-43.
Miller AB. Cervical cancer screening programmes: managerial guidelines. World Health Organization, Geneva, 1992.
Miller AB, Lindsay J, Hill GB. Mortality from cancer of the uterus in Canada and its relationship to screening for cancer of the cervix. Int J Cancer 1976;17:602-612.
Miller AB, Nazeer S, Fonn S, Brandup-Lukanow A, Rehman R, Cronje H, et al. Report on consensus conference on cervical cancer screening and management. Int J Cancer 2000;86:440-447.
Morrison EAB, Ho GYF, Vermund SH, Golsberg GL, Kadish AS, Kelley KF, et al. Human papillomavirus infection and other risk factors for cervical neoplasia: a case-control study. Int J Cancer 1991;49:6-13.
Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527.
Nieminen P, Kallio M, Anttila A, Hakama M. Organised vs. spontaneous Pap-smear screening for cervical cancer: A case-control study. Int J Cancer 1999;83:55-58.
Olatunbosun O, Deneer H, Pierson R. Human papillomavirus DNA detection in sperm using polymerase chain reaction. Obstet Gynecol 2001;97:357-360.
Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993;12:186-192. Park TW, Richart RM, Sun XW, Wright TC Jr. Association between human papillomavirus type and clonal status of cervical squamous intraepithelial lesions. J Natl Cancer Inst 1996;88:355-358.
Paraskevaidis E, Arbyn M, Sotiriadis A, Diakomanolis E, Martin-Hirsch P, Koliopoulos G, et al. The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev. 2004;30:205-211.
Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827-841.
Perrons C, Kleter B, Jelley R, Jalal H, Quint W, Tedder R. Detection and genotyping of human papillomavirus DNA by SPF10 and MY09/11 primers in cervical cells taken from women attending a colposcopy clinic. J Med Virol 2002;67:246-252
Petignat P, Faltin D, Goffin F, Billieux MH, Stucki D, Sporri S, Vassilakos P. Age-related performance of human papillomavirus testing used as an adjunct to cytology for cervical carcinoma screening in a population with a low incidence of cervical carcinoma. Cancer. 2005 ;105:126-132.
Poten J, Adami H-O, Bergström R, et al. Strategies for global control of cervical cancer. Int J Cancer 1995;60:1-26. Quinn M, Babb P, Jones J, Allen E. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 1999;318:904-908.
Raab S. The cos-effectiveness of cervical-vaginal rescreening. Am J Clin Pathol 1997;108:525-536.
Richart RM, Barron BA. A follow-up study of patients with cervical dysplasia. Am J Obstet Gynecol 1969;105:386-393.
Riethmuller D, Gay C, Bertrand X, Bettinger D, Schaal JP, Carbillet JP, et al. Genital human papillomavirus infection among women recruited for routine cervical cancer screening or for colposcopy determined by Hybrid Capture II and polymerase chain reaction. Diagn Mol Pathol 1999;8:157-164.
Rozendaal L, Walboomers JM, van der Linden JC, et al. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer 1996;68:766-769.
Sanjosé S de, Muñoz N, Bosch FX, Reimann K, Pedersen NS, Orfila J, et al. Sexually transmitted agents and cervical neoplasis in Colombia and Spain. Int J Cancer 1994;56:358-363.
Sanjose S de, Almirall R, Lloveras B, Font R, Diaz M, Munoz N, et al. Cervical human papillomavirus infection in the female population in Barcelona, Spain. Sex Transm Dis 2003;30:788-793.
Sasieni P, cuzick J, Farmery E. Accelerated decline in cervical cancer mortality in England and Wales. Lancet 1995;346:1566-1567.
Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, Franco EL. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001;286:3106-3114.
Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85:958–964.
Schiffman M, Herrero R, Hildesheim A, Sherman ME, Bratti M, Wacholder S, et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 2000;283:87-93.
Schiffman M, Khan MJ, Solomon D, Herrero R, Wacholder S, Hildesheim A, et al; PEG Group; ALTS Group. A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst. 2005 Jan 19;97(2):147-50.
Sherlaw-Johnson C, Gallivan S, Jenkins D. Evaluating cervical cancer screening programmes for developing countries. Int J Cancer 1997;72:210-216.
Sherlaw-Johnson C, Gallivan S, Jenkins D. Withdrawing low risk women from cervical screening programmes: mathematical modelling study. BMJ 1999;318:356-360.
Sherman ME, Mendoza M, Lee KR, Ashfaq R, Birdsong GG, Corkill ME, et al. Performance of liquid-based, thin-layer cervical cytology: correlation with reference diagnoses and human papillomavirus testing. Mod Pathol 1998;11:837-843.
Sherman ME, Schiffman M, Cox JT; Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study Group. Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). J Natl Cancer Inst 2002;94:102-107.
Sigurdsson K. Cervical cancer, Pap smear and HPV testing: an update of the role of organized Pap smear screening adn HPV testing. Acta Obstet Gynecol Scand 1999;78:467-477.
Solomon D, Frable WJ, Vooijs P, Wilbur DC, Amma S, Collins RJ, et al, ASCUS and AGUS criteria: IAC task force summary. Acta Cytol 1998;42:16-24.
Strauss S, Jordens Z, Desselberger U, Gray JJ. Single-tube real-time nested polymerasen chain reaction for detecting human papillomavirus DNA. Diagn Mol Pathol 2000;9:151-157.
Sutton G. The cervical screening muddle. Lancet 1998;351:1129.
Taylor LA, Sorensen SV, Ray NF, Halpern MT, Harper DM. Cost-effectiveness of the conventional papanicolaou test with a new adjunct to cytological screening for squamous cell carcinoma of the uterine cervix and its precursors. Arch Fam Med 2000;9:713-721.
The revised Bethesda System for reporting cervical/vaginal cytologic diagnoses: Report of the 1991 Bethesda Workshop. Acta Cytol 1992;36:273-276.
Thornton H. The cervical screening muddle. Lancet 1998;351:1130-1131.
Van Ballegooijen M, van den Akker-van Marle ME, Warmerdam PG, Meijer CJ, Walboomers JM, Habbema JD. Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the cost- effectiveness. Br J Cancer 1997;76:651-671.
Van Oortmarssen GJ, Habbema JDF. Epidemiologic evidence for age-dependent regression of pre-invasive cervical cancer. Br J Cancer 1991;64:559-565.
Vassilakos P, Petignat P, Boulvain M, Campana A. Primary screening for cervical cancer precursors by the combined use of liquid-based cytology, computer-assisted cytology and HPV DNA testing. Br J Cancer 2002;86:382-388.
Velasco J, Fernandez Blanco C, Lopez Carrascosa I, Cueto Espinar A, Sampedro A. Disappearance of DNA HPV in sequential specimens of occult cervical infection in a "normal" population. Eur J Gynaecol Oncol 1996;:372-377.
Walboomers JM, Husman AM, Snijders PJ, Stel HV, Risse EK, Helmerhorst TJ, et al. Human papillomavirus in false negative archival cervical smears: implications for screening for cervical cancer. J Clin Pathol 1995;48:728-732.
Womack C, Warren AY. The cervical screening muddle. Lancet 1998;351:1129.
Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ; ASCCP-Sponsored Consensus Conference. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 2002;287:2120-2129.
Wright TC Jr, Denny L, Kuhn L, Pollack A, Lorincz A. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 2000;283:81-86.
Zheng P-S, Li S-R, Iwasaka T, Song J, Cui M-H, Sugimori H. Simultaneous detection by consensus multiplex PCR of high and low-risk and other types of human papilloma virus in clinical samples. Gynecol Oncol 1995;58:179-183. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000;92:690-698.
|